Reducing inappropriate antibiotic prescribing in primary care is a key element of antimicrobial stewardship. This study carried out in GP surgeries in Cornwall examined whether clarithromycin was being prescribed in accordance with NICE guidance, and whether allergy status and symptoms were correctly recorded in the case of patients who had penicillin allergy noted.
{"title":"Improving antimicrobial stewardship in general practice","authors":"Marco Motta, M. Wilcock","doi":"10.1002/psb.2041","DOIUrl":"https://doi.org/10.1002/psb.2041","url":null,"abstract":"Reducing inappropriate antibiotic prescribing in primary care is a key element of antimicrobial stewardship. This study carried out in GP surgeries in Cornwall examined whether clarithromycin was being prescribed in accordance with NICE guidance, and whether allergy status and symptoms were correctly recorded in the case of patients who had penicillin allergy noted.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84187092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.
{"title":"Rimegepant for the prevention and treatment of migraine","authors":"S. Chaplin","doi":"10.1002/psb.2044","DOIUrl":"https://doi.org/10.1002/psb.2044","url":null,"abstract":"Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83427455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.
{"title":"Icosapent ethyl for reducing the risk of cardiovascular events","authors":"S. Chaplin","doi":"10.1002/psb.2045","DOIUrl":"https://doi.org/10.1002/psb.2045","url":null,"abstract":"Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79734980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
First reported in Western medical literature in the 1950s, faecal microbiota transplant (FMT) has now come of age as a cost‐effective treatment for recurrent Clostridioides difficile infection. But what do we know about FMT, what are its uses and limitations, and where might microbiome treatments take us in the future?
{"title":"Realising the potential of faecal microbiota transplant","authors":"Angela Dowden","doi":"10.1002/psb.2043","DOIUrl":"https://doi.org/10.1002/psb.2043","url":null,"abstract":"First reported in Western medical literature in the 1950s, faecal microbiota transplant (FMT) has now come of age as a cost‐effective treatment for recurrent Clostridioides difficile infection. But what do we know about FMT, what are its uses and limitations, and where might microbiome treatments take us in the future?","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73821454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The monoamine hypothesis of depression has dominated treatment for decades, but for some with treatment‐resistant depression, alternative approaches are needed. This article discusses some of the other mechanisms involved in depression and how novel treatments could address these.
{"title":"New antidepressants: monoamines and beyond","authors":"M. Greener","doi":"10.1002/psb.2032","DOIUrl":"https://doi.org/10.1002/psb.2032","url":null,"abstract":"The monoamine hypothesis of depression has dominated treatment for decades, but for some with treatment‐resistant depression, alternative approaches are needed. This article discusses some of the other mechanisms involved in depression and how novel treatments could address these.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82049268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inclisiran (Leqvio) is a first‐in‐class cholesterol‐lowering small interfering RNA (siRNA) that works through gene silencing. Even though it has been approved by NICE and a population health agreement is in place, uptake in general practice has been slow. This article examines the barriers to uptake and how these could be addressed.
{"title":"The novel siRNA inclisiran and population health management","authors":"L. Walker","doi":"10.1002/psb.2037","DOIUrl":"https://doi.org/10.1002/psb.2037","url":null,"abstract":"Inclisiran (Leqvio) is a first‐in‐class cholesterol‐lowering small interfering RNA (siRNA) that works through gene silencing. Even though it has been approved by NICE and a population health agreement is in place, uptake in general practice has been slow. This article examines the barriers to uptake and how these could be addressed.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88508234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lithium has an important role in the management of bipolar disorder and treatment‐resistant depression but its narrow therapeutic window means that careful monitoring is needed. This article discusses the investigations, monitoring requirements, drug interactions and complications to be aware of to ensure lithium prescribing is as safe as possible.
{"title":"The highs and lows of prescribing and monitoring lithium safely","authors":"Aisling Molloy","doi":"10.1002/psb.2034","DOIUrl":"https://doi.org/10.1002/psb.2034","url":null,"abstract":"Lithium has an important role in the management of bipolar disorder and treatment‐resistant depression but its narrow therapeutic window means that careful monitoring is needed. This article discusses the investigations, monitoring requirements, drug interactions and complications to be aware of to ensure lithium prescribing is as safe as possible.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86715237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ryeqo is a combined formulation of relugolix, estradiol and norethisterone for the treatment of moderate to severe symptoms of uterine fibroids. This article outlines its efficacy, adverse effects and place in therapy.
{"title":"Ryeqo for the treatment of the symptoms of uterine fibroids","authors":"S. Chaplin","doi":"10.1002/psb.2036","DOIUrl":"https://doi.org/10.1002/psb.2036","url":null,"abstract":"Ryeqo is a combined formulation of relugolix, estradiol and norethisterone for the treatment of moderate to severe symptoms of uterine fibroids. This article outlines its efficacy, adverse effects and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79955786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：